Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.

Item

http://www.wikidata.org/entity/Q36097737

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@ast

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@en

type

Item

label

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@ast

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@en

prefLabel

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@ast

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@en

P1476

Pazolimus: pazopanib plus siro ...... spective case series analysis.

@en

P2093

F Eleyan

http://www.w3.org/2001/XMLSchema#string

O Merimsky

http://www.w3.org/2001/XMLSchema#string

S Gill

http://www.w3.org/2001/XMLSchema#string

T Peretz

http://www.w3.org/2001/XMLSchema#string

Y Azraq

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity

Modes of resistance to anti-angiogenic therapy

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Response to imatinib plus sirolimus in advanced chordoma.

Angiogenesis inhibition in non-GIST soft tissue sarcomas.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

P2888

s12885-016-2618-1

P304

616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2618-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

D Katz

P577

2016-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013246309

http://www.w3.org/2001/XMLSchema#string

P698

27501793

http://www.w3.org/2001/XMLSchema#string

P932

4977830

http://www.w3.org/2001/XMLSchema#string